Management of relapsing Plasmodium vivax malaria

TitleManagement of relapsing Plasmodium vivax malaria
Publication TypeJournal Article
Year of Publication2016
AuthorsChu, CS, White, NJ
JournalExpert Rev Anti Infect Ther
Date PublishedAug 17
ISBN Number1744-8336 (Electronic)1478-7210 (Linking)
Keywords8-aminoquinoline, Anti-malarial efficacy, Chloroquine, Glucose-6-phosphate dehydrogenase deficiency, Plasmodium vivax, Plasmodium vivax relapse, Plasmodium vivax treatment, Primaquine, Radical cure, Review
Abstract

Introduction Relapses are important contributors to illness and morbidity in Plasmodium vivax and ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms "P. vivax" and "relapse". Areas covered Hypnozoites causing relapses may be activated weeks or months after initial infection. Incidence and temporal patterns of relapse varies geographically. Relapses derive from parasites either genetically similar or different from the primary infection indicating that some derive from previous infections. Malaria illness itself may activate relapse. Primaquine is the only widely available treatment for radical cure. However, it is often not given because of uncertainty over the risks of primaquine induced haemolysis when G6PD deficiency testing is unavailable. Recommended dosing of primaquine for radical cure in East Asia and Oceania is 0.5mg base/kg/day and elsewhere is 0.25mg base/kg/day. Alternative treatments are under investigation. Expert commentary Geographic heterogeneity in relapse patterns and chloroquine susceptibility of P. vivax, and G6PD deficiency epidemiology mean that radical treatment should be given much more than it is today. G6PD testing should be made widely available so primaquine can be given more safely.

URLhttp://www.ncbi.nlm.nih.gov/pubmed/27530139